Literature DB >> 12898226

Human serum antibodies against shared antigens of different stages of Trichinella spiralis: relevance of glycan and protein epitopes.

S L Malmassari1, S N Costantino, R F Iacono, S M Venturiello.   

Abstract

Taking into account that antibodies against the surface antigens of newborn larvae (anti-NBL Abs) present in sera from individuals with chronic trichinellosis recognize antigenic determinants of the excretory-secretory muscle larva products (ML-ESP), and that these products are mainly glycoproteins, the aim of this work was to assess the frequency of anti-NBL Abs in sera from individuals with acute and chronic trichinellosis, to analyse the relevance of glycan and protein epitopes of the ML-ESP in the cross-reactivity phenomenon, and its correlation with the host's serum response towards these products. Anti-NBL surface Abs were determined in sera by indirect immunofluorescence. The degree of recognition by serum and purified anti-NBL Abs was evaluated comparatively before and after chemical deglycosylation of ML-ESP by immunoelectrotransfer blot assay. Results showed that 64% of the sera from individuals with acute trichinellosis and 35% of those belonging to the chronic phase had anti-NBL Abs, and also that the protein epitopes are the major ones responsible for the cross-reactivity phenomenon involving the ML-ESP and the NBL surface during both phases of the infection, while glycan epitopes are immunodominant in the stimulation of the host's immune system. A modulatory phenomenon in the immune response generated towards Trichinella spiralis NBL driven by the ML-ESP is postulated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898226     DOI: 10.1007/s00436-003-0931-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  27 in total

1.  Identification of Schistosoma mansoni glycolipids that share immunogenic carbohydrate epitopes with glycoproteins.

Authors:  J B Weiss; J L Magnani; M Strand
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  Deglycosylation of glycoproteins by trifluoromethanesulfonic acid.

Authors:  A S Edge; C R Faltynek; L Hof; L E Reichert; P Weber
Journal:  Anal Biochem       Date:  1981-11-15       Impact factor: 3.365

3.  Cytotoxicity-blocking antibodies in human chronic trichinellosis.

Authors:  S M Venturiello; S L Malmassari; S N Costantino; G G Nuñez
Journal:  Parasitol Res       Date:  2000-09       Impact factor: 2.289

Review 4.  Clinical aspects of infection with Trichinella spp.

Authors:  V Capó; D D Despommier
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

5.  Characterization of a series of novel fucose-containing glycosphingolipid immunogens from eggs of Schistosoma mansoni.

Authors:  S B Levery; J B Weiss; M E Salyan; C E Roberts; S Hakomori; J L Magnani; M Strand
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

6.  Blocking anti-Trichinella spiralis antibodies in chronically infected rats.

Authors:  S M Venturiello; S N Costantino; G H Giambartolomei
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

7.  Characterization of surface antigens of Trichinella spiralis infective larvae.

Authors:  R M Parkhouse; M Philipp; B M Ogilvie
Journal:  Parasite Immunol       Date:  1981       Impact factor: 2.280

8.  Characterization of nematode glycoproteins: the major O-glycans of Toxocara excretory-secretory antigens are O-methylated trisaccharides.

Authors:  K H Khoo; R M Maizels; A P Page; G W Taylor; N B Rendell; A Dell
Journal:  Glycobiology       Date:  1991-03       Impact factor: 4.313

Review 9.  Opinion on the diagnosis and treatment of human trichinellosis.

Authors:  Jean Dupouy-Camet; Wanda Kociecka; Fabrizio Bruschi; Francisco Bolas-Fernandez; Edoardo Pozio
Journal:  Expert Opin Pharmacother       Date:  2002-08       Impact factor: 3.889

10.  Immune response to stage-specific surface antigens of the parasitic nematode Trichinella spiralis.

Authors:  M Philipp; P M Taylor; R M Parkhouse; B M Ogilvie
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.